PLYX

Polaryx Therapeutics, Inc. PLYX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$5.83M total
VANGUARD CAPITAL MANAGEMENT LLC
$4.41M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$455.1K+0.2%
VANGUARD FIDUCIARY TRUST CO
$279.5K+0.5%
HRT FINANCIAL LP
$218.0KNew
STATE STREET CORP
$154.6K0.0%
BlackRock, Inc.
$109.1K0.0%
JANE STREET GROUP, LLC
$83.6KNew
NORTHERN TRUST CORP
$74.4K0.0%
Allworth Financial LP
$20.6KNew
Vanguard Global Advisers, LLC
$16.8K0.0%
Tower Research Capital LLC (TRC)
$8.0K+68.6%
UBS Group AG
$3.4K-90.5%
Fortitude Family Office, LLC
$503New
See all 13 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PLYX

Earnings Per Share

13fpro.ai/company/PLYX

Loading ratio trend…

PLYX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Polaryx Therapeutics, Inc. (PLYX): stock profile, AI score and financials

Polaryx Therapeutics, Inc. (PLYX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PLYX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of PLYX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. PLYX trades on the Nasdaq exchange and files with the SEC under CIK 2075320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Polaryx Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2075320 →